Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Cdt1 Double Nickase Plasmid (h): sc-401014-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cdt1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Cdt1 Double Nickase Plasmid (h) and Cdt1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CDT1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cdt1 Antibody (F-6): sc-365305
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdt1 Double Nickase Plasmid (h) | sc-401014-NIC | 20 µg | $410.00 | |||
Cdt1 Double Nickase Plasmid (h2) | sc-401014-NIC-2 | 20 µg | $410.00 |
Human CDT1 encodes Cdt1, an essential replication licensing factor that loads the MCM2–7 helicase onto chromatin during late mitosis and G1 to establish pre-replication complexes and ensure once-per-cell-cycle DNA replication. Cdt1 activity is tightly controlled by CDK-dependent phosphorylation and ubiquitin-mediated proteolysis via SCF and CRL4–DDB1–Cdt2 pathways, integrating replication origin licensing with checkpoint signaling and chromatin context. Dysregulated CDT1 expression or stabilization promotes re-replication, replication stress, and DNA damage responses, linking Cdt1 to genome instability phenotypes studied in cancer biology and other proliferative disorders. As a node in S-phase entry control, Cdt1 is frequently examined alongside geminin (GMNN), ORC components, and ATR/CHK1 pathways to dissect replication timing and cell-cycle progression.
Cdt1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CDT1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CDT1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CDT1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CDT1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.